Form 4 for OVID Ovid Therapeutics Inc.
Accepted 2025-12-09 00:00:00 ET · period of report 2025-12-08 · accession 0001395064-25-000172 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-12-09 | 2025-12-08 | OVID | Takeda Pharmaceuticals U.S.A., Inc. | 10% | C - Cnv Deriv | $0.00 | +1.25M | 7.00M | +22% | $0 |
| DI | 2025-12-09 | 2025-12-08 | OVID | Takeda Pharmaceuticals U.S.A., Inc. | 10% | C - Cnv Deriv | $0.00 | -1,250 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-08 | C | A | 1,250,000 | $0.00 | 7,000,000 | I See Explanation of Responses | — | — | (F1) Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA. (F2) The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA. |
| 2 | Derivative | Series A Convertible Preferred Stock | 2025-12-08 | C | D | 1,250 | $0.00 | 0 | I See Explanation of Responses | $0.00 · — to — | 1,250 Common Stock | (F2) The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA. (F1) Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA. (F3) The Preferred Stock had no expiration date. |